<DOC>
	<DOCNO>NCT01169987</DOCNO>
	<brief_summary>This observational study document extent daily clinical practice Humira ( adalimumab ) therapy continue , interrupt permanently discontinue follow-up period 2 year . Reasons interrupt permanently discontinue Humira therapy reason restart Humira therapy note . An evaluation perform effect disease quality life work productivity .</brief_summary>
	<brief_title>Evaluation Humira Retention Rate Psoriasis Patients Daily Practice Assessment Work Productivity Quality Life</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients &gt; = 18 year Patient chronic plaque psoriasis Patient newly initiate Humira Patient compliant Humira Summary Product Characteristics Patient compliant Belgian reimbursement criterion Humira plaque psoriasis Patient sign informed consent Patients contraindication mention Summary Product Characteristics Humira Patients willing sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multicenter study</keyword>
</DOC>